NZ523073A - Systems and methods for treating a mucosal surface - Google Patents

Systems and methods for treating a mucosal surface

Info

Publication number
NZ523073A
NZ523073A NZ523073A NZ52307301A NZ523073A NZ 523073 A NZ523073 A NZ 523073A NZ 523073 A NZ523073 A NZ 523073A NZ 52307301 A NZ52307301 A NZ 52307301A NZ 523073 A NZ523073 A NZ 523073A
Authority
NZ
New Zealand
Prior art keywords
amines
mucosal surface
irm
treating
systems
Prior art date
Application number
NZ523073A
Inventor
John Charles Hedenstrom
Michael John Jozwiakowski
Mark Manuel Martinez
Kenneth Robert Phares
Kenneth Frank Trofatter
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/676,339 external-priority patent/US6486168B1/en
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of NZ523073A publication Critical patent/NZ523073A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A system for treating a condition associated with a mucosal surface, the system comprising an immune response modifier (IRM) compound chosen from imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, 1,2-bridged imidazoquinoline amines, and pharmaceutically acceptable salts thereof and an applicator device for applying the IRM compound to the mucosal surface. This system of IRM compounds and applicator may be used to treat conditions associated with mucosal surfaces such as cervical dysphasia and cervical intraepithelial neoplasia
NZ523073A 2000-06-22 2001-06-22 Systems and methods for treating a mucosal surface NZ523073A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21342000P 2000-06-22 2000-06-22
US09/676,339 US6486168B1 (en) 1999-01-08 2000-09-29 Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
PCT/US2001/019979 WO2001097795A2 (en) 2000-06-22 2001-06-22 Systems and methods for treating a mucosal surface

Publications (1)

Publication Number Publication Date
NZ523073A true NZ523073A (en) 2005-04-29

Family

ID=26908067

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ523073A NZ523073A (en) 2000-06-22 2001-06-22 Systems and methods for treating a mucosal surface

Country Status (17)

Country Link
EP (1) EP1296644A2 (en)
JP (1) JP2004508851A (en)
CN (1) CN1273110C (en)
AU (1) AU2001270081A1 (en)
BR (1) BR0112386A (en)
CA (1) CA2410208A1 (en)
CZ (1) CZ20024175A3 (en)
EE (1) EE200200705A (en)
HR (1) HRP20021024A2 (en)
HU (1) HUP0301233A2 (en)
IL (1) IL153087A0 (en)
MX (1) MXPA02012524A (en)
NO (1) NO20026067L (en)
NZ (1) NZ523073A (en)
PL (1) PL361975A1 (en)
SK (1) SK17812002A3 (en)
WO (1) WO2001097795A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
WO2004037175A2 (en) 2002-10-21 2004-05-06 Mgi Pharma Biologics, Inc. Compositions and methods for treating human papillomavirus-mediated disease
EP1686935A4 (en) * 2003-10-22 2009-06-17 Univ Cleveland Hospitals Method and apparatus for applying medication to internal tissue
AU2006210392A1 (en) * 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939090A (en) * 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
NZ512628A (en) * 1999-01-08 2004-03-26 3M Innovative Properties Co Formulations and methods for treatment of mucosal associated conditions with an immune response modifier

Also Published As

Publication number Publication date
MXPA02012524A (en) 2003-04-10
WO2001097795A3 (en) 2002-04-04
WO2001097795A2 (en) 2001-12-27
JP2004508851A (en) 2004-03-25
PL361975A1 (en) 2004-10-18
NO20026067D0 (en) 2002-12-17
CA2410208A1 (en) 2001-12-27
NO20026067L (en) 2003-02-17
EE200200705A (en) 2004-08-16
CZ20024175A3 (en) 2003-06-18
CN1437463A (en) 2003-08-20
BR0112386A (en) 2003-06-10
CN1273110C (en) 2006-09-06
IL153087A0 (en) 2003-06-24
HUP0301233A2 (en) 2003-08-28
AU2001270081A1 (en) 2002-01-02
HRP20021024A2 (en) 2005-02-28
SK17812002A3 (en) 2003-05-02
EP1296644A2 (en) 2003-04-02

Similar Documents

Publication Publication Date Title
HU229441B1 (en) Formulations and methods for treating mucosal associated conditions with an immune response modifier
EP1495758A3 (en) Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
WO2005016275A3 (en) Formulations containing an immune response modifier
ES2185808T3 (en) PROCEDURE TO PREPARE TETRAHYDROIMIDAZOQUINOLINAMINAS.
WO2006084251A3 (en) Aqueous gel formulations containing immune reponse modifiers
WO2001074343A3 (en) Method for the treatment of dermal lesions caused by envenomation
HK1073778A1 (en) Pharmaceutical formulations comprising an immune response modifier
PL365445A1 (en) Beta-carboline derivatives useful as inhibitors of phosphodiesterase
HK1069970A1 (en) Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
BRPI0519797A (en) Method for the preparation of 2-methyl-1- (2-methylpropyl) -1h-imidazo [4,5-c] [1,5] naphthyridin-4-amine, Method for obtaining n4- (2-methylpropyl) -3-nitro [1,5] naphthyridin-4-amine and method for obtaining 2-methyl-1- (2-methylpropyl) -5-oxido-1h-imidazo [4,5-c] [1,5 ] naphthyridine
JP2006517974A5 (en)
AU2001272326A1 (en) Method and device for the detection and evaluation of surface damage to laid tracks and points components
NO20031722D0 (en) New 7-azaindoles, use of the same as phosphodiesterase-4 inhibitors and method of preparing the same
NZ523073A (en) Systems and methods for treating a mucosal surface
HK1049189A1 (en) Method and device for applying an anti-corrosive coating
WO2001044235A3 (en) Agents and methods for the treatment of proliferative diseases
CA2643679C (en) Immune response modifier formulations containing oleic acid and methods
AU2001277831A1 (en) Method for measuring electrical parameters of a skin integument and the mucous coat and device for carrying out said method
AU2002302631A1 (en) Method and device for short-term thermal treatment of flat objects
AU2002257656A1 (en) Method and device for detecting the location of faults in insulated conduit systems
UA32347A (en) Jet gripping device

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, JP

Free format text: OLD OWNER(S): 3M INNOVATIVE PROPERTIES COMPANY

RENW Renewal (renewal fees accepted)